Focused on the Cure
Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients.
One of the most exciting advances in cancer research is an innovative approach that involves removing a patient’s immune cells, modifying those cells to identify specific antigens, then infusing those cells in the patient to fight cancer. We have long believed in the promise of modifying T cells to treat certain blood cancers and our singular focus is developing cell therapy.
We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.
We have one of the leading pipelines in cell therapy within the industry.
Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.
We have an unwavering commitment to developing and gaining the approval of innovative therapies. Our focus is on providing therapeutic options that healthcare providers can use to make a difference in the lives of their patients.
Adoptive immunotherapy may solve problems of patients with cancer that can’t be solved any other way.
— Steven Rosenberg, M.D., Ph.D., Chief of Surgery at the U.S. National Cancer Institute and Kite Collaborator